All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Where are we on anti-BCMA CAR T-cell therapies for MM?

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to the Co-Chair of the hub, María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, Where are we on anti-BCMA CAR T-cell therapies for MM?

María-Victoria Mateos talks about idecabtagene vicleucel (ide-cel) and the results of the KarMMa trial, in addition to ciltacabtagene autoleucel (cilta-cel), in patients with relapsed/refractory MM. Maria


Subscribe to get the best content related to multiple myeloma delivered to your inbox